Original Article
International Journal of Obesity (2009) 33, 123–130; doi:10.1038/ijo.2008.224; published online 9 December 2008
Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study
S Söderberg1, D Colquhoun2, A Keech3, J Yallop4, E H Barnes3, C Pollicino3, J Simes3, A M Tonkin5 and P Nestel6 for the LIPID Study Investigators
- 1Department of Public Health and Clinical Medicine, Cardiology, Umeå University, Umeå, Sweden
- 2Core Research, University of Queensland, Brisbane, Queensland, Australia
- 3National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia
- 4Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
- 5Department of Epidemiology and Preventive Medicine, Monash University, and National Heart Foundation of Australia, Melbourne, Victoria, Australia
- 6Baker Heart Research Institute, Melbourne, Victoria, Australia
Correspondence: Dr S Söderberg, Department of Public Health and Clinical Medicine, Cardiology, Umeå University Hospital, Umeå SE-901 85, Sweden. E-mail: stefan.soderberg@medicin.umu.se
Received 19 May 2008; Revised 23 September 2008; Accepted 5 October 2008; Published online 9 December 2008.
Abstract
Objective:
To investigate the relationships between plasma leptin and adiponectin levels and recurrent cardiovascular events (cardiovascular death, nonfatal myocardial infarction and stroke) in men with earlier acute coronary syndromes.
Design, subjects and measurements:
A nested case–control study examined circulating leptin and adiponectin levels in plasma obtained 4–6 years after entry into the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) trial. Plasma was assayed from 184 men who suffered recurrent events within 4.4 years after blood collection and 184 matched controls who remained free of further events. The association between cardiovascular events and the explanatory variables was examined by conditional logistic regression analysis.
Results:
Relative risk (RR) increased across increasing leptin quartiles; the highest quartile compared with the lowest quartile was related to the highest risk (P for trend=0.002); the increased risk remained after adjustment for risk factors (P=0.018) or for obesity (P=0.038), but in the final model (adjusted for randomized treatment, other drugs, LIPID risk score, age and body mass index), the risk was attenuated (RR=1.61, 95% CI: 0.72–3.57, P for trend=0.34). Adiponectin did not predict cardiovascular events. Subjects randomly allocated to pravastatin had 6% lower leptin levels (P=0.04) than those allocated to placebo.
Conclusion:
Plasma leptin was a significant and independent predictor of recurrent cardiovascular events (cardiovascular death, nonfatal myocardial infarction and stroke) in men with earlier acute coronary syndromes.
Keywords:
leptin, adiponectin, cardiovascular disease, risk prediction, pravastatin, atherosclerosis
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Cardiac biomarkers: a contemporary status report
Nature Clinical Practice Cardiovascular Medicine Review (01 Jan 2006)
Cardiac biomarkers: a contemporary status report
Nature Clinical Practice Cardiovascular Medicine Review (01 Jan 2006)
NEWS AND VIEWS
American Journal of Hypertension News and Views
Acute coronary syndromes BNP measurement predicts AMI risk in the elderly
Nature Reviews Cardiology News and Views (01 Aug 2009)
RESEARCH
Kidney International Original Article
